InsidersTradesSigma
Total declarations
Companies
▲ Purchases (7 ops.)
▼ Sales (0 ops.)
Insider track record
Board DirectorDisclosed buys
7
Disclosed sells
0
T+90 hit rate
29%
T+90 mean return
-17.7%
Across 7 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Browse the detailed record of transactions filed by Feinberg Peter, Director. Insider active across 2 companies, notably Immuneering Corp. In total, 10 filings have been published. Breakdown: 7 buys · 0 sell. Total volume traded: €603k. Activity tracked since 13 September 2021. The latest transaction was disclosed on 8 May 2024 (Attribution). Regulator: SEC (Form 4). All data is accessible without signup.
Declarations10 total
40,247 shares0Ordinary SharesSEC:0001062993-24-009929:0
25,000 shares@ US$2.54859.7% of flowClass A Common StockSEC:0001790340-24-000042:0
Ideal exit: 17 Dec 2024 (T+270)
45,024 shares@ US$2.306715.8% of flowClass A Common StockSEC:0001790340-24-000028:0
Ideal exit: 13 Dec 2024 (T+270)
6,667 shares@ US$6.750.012% mcap9.2% of flowClass A Common StockSEC:0001415889-22-003061:0
Ideal exit: 10 Dec 2022 (T+270)
4,750 shares@ US$24.4450.030% mcap22.1% of flowClass A Common StockSEC:0001415889-21-004512:0
Ideal exit: 17 Jun 2022 (T+270)
4,750 shares@ US$24.44516.4% of flowClass A Common StockSEC:0001415889-21-004512
Ideal exit: 17 Jun 2022 (T+270)
5,750 shares@ US$21.51260.031% mcap23.3% of flowClass A Common StockSEC:0001415889-21-004407:0
Ideal exit: 10 Jun 2022 (T+270)
5,750 shares@ US$21.512617.4% of flowClass A Common StockSEC:0001415889-21-004407
Ideal exit: 10 Jun 2022 (T+270)
133,572 sharesClass A Common StockSEC:0001104659-21-099742
133,572 sharesClass A Common StockSEC:0001104659-21-099742:0
10 of 10 declarations
About Feinberg Peter
Peter Feinberg is a Director at Immuneering Corp. In this role, he participates in strategic decision-making and governance of the company. Feinberg brings valuable experience in leadership and management, helping to guide growth initiatives and ensure regulatory compliance. His commitment to operational excellence is an asset to the board.
